TORONTO, May 11, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three months ended March 31, 2023, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com.
“We began 2023 with record first-quarter revenue with continued robust positive year-over-year and sequential momentum,” said Dan Matlow, Chief Executive Officer of VitalHub. “Positive organic growth (17%) and accretive inorganic growth contributed to our 34% Q1 2023 revenue increase. Strong double-digit year-over-year growth in term licences, maintenance and support, and triple digit growth in services and hardware, more than offset the year-over-year decline in perpetual licenses. We announced the acquisition of Coyote Software Corporation, our sixteenth acquisition since 2017. ARR (1,2) benefited from positive organic and inorganic growth and benefited from a gain due to the increase in the value of the GBP pound relative to the CAD dollar from Q4 2022. ARR (1,2) increased 65% or $15.6 million to $39.6 million from Q1 2022. Adjusted EBITDA (2) was strong at $2.9 million, representing 23% of revenue. We closed the quarter with $17.2 million in cash on hand and, combined with the availability of a Bank of Nova Scotia Facility, we currently have $50.2 million at our disposal for operations and to continue progressing our acquisition strategy. As evidenced by recent announcements (relating to SHREWD, TREAT and College of Optometrists), we are penetrating deeper into core accounts and expanding horizontally into adjacent markets and look forward to continuing this momentum in 2023.”
VitalHub Corp’s quarterly investor conference call will take place on Friday, May 12, 2023, at 9:00AM EST.
To register for the call, please visit: Click Here
First Quarter 2023 Highlights
(1) The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions.
(2) Non-IFRS measure.
Q1 2023 Results
Three months ended | ||||||||||
March 31, 2023 | % Revenue | March 31, 2022 | % Revenue | Change | ||||||
$ | $ | % | ||||||||
Revenue | 12,595,174 | 100 | % | 9,423,191 | 100 | % | 34 | % | ||
Cost of sales | 2,471,877 | 20 | % | 1,474,579 | 16 | % | (68 | %) | ||
Gross profit | 10,123,297 | 80 | % | 7,948,612 | 84 | % | 27 | % | ||
Operating expenses | ||||||||||
General and administrative | 3,611,092 | 29 | % | 1,845,516 | 20 | % | (96 | %) | ||
Sales and marketing | 1,281,665 | 10 | % | 1,048,389 | 11 | % | (22 | %) | ||
Research and development | 2,520,021 | 20 | % | 2,024,367 | 21 | % | (24 | %) | ||
Depreciation of property and equipment | 75,283 | 1 | % | 43,317 | 0 | % | (74 | %) | ||
Depreciation of right-of-use assets | 95,907 | 1 | % | 63,389 | 1 | % | (51 | %) | ||
Stock based compensation | 277,684 | 2 | % | 269,244 | 3 | % | (3 | %) | ||
Foreign currency gain | (213,261 | ) | (2 | %) | (20,675 | ) | (0 | %) | (931 | %) |
Other income and expenses | ||||||||||
Amortization of intangible assets | 1,054,247 | 8 | % | 683,928 | 7 | % | (54 | %) | ||
Business acquisition, restructuring and integration costs | 658,349 | 5 | % | 414,727 | 4 | % | (59 | %) | ||
Interest expense and accretion (net of interest income) | (38,987 | ) | (0 | %) | (4,720 | ) | (0 | %) | (726 | %) |
Interest expense from lease liabilities | 20,869 | 0 | % | 17,618 | 0 | % | (18 | %) | ||
Current and deferred income taxes | 618,260 | 5 | % | 125,901 | 1 | % | (391 | %) | ||
Net income | 162,168 | 1 | % | 1,437,611 | 15 | % | (89 | %) | ||
EBITDA (Non-IFRS measure) | 1,987,747 | 16 | % | 2,367,044 | 25 | % | (16 | %) | ||
Adjusted EBITDA (Non-IFRS measure) | 2,923,780 | 23 | % | 3,051,015 | 32 | % | (4 | %) | ||
Annual recurring revenue (Non-IFRS measure) | 39,634,517 | 24,015,090 | 65 | % | ||||||
Term licences, maintenance and support revenue | 9,997,484 | 79 | % | 5,732,891 | 61 | % | 74 | % | ||
As at | ||||||||||
March 31, 2023 | December 31, 2022 | |||||||||
$ | $ | |||||||||
Deferred revenue | 16,671,903 | 15,495,461 | ||||||||
Cash balance | 17,167,716 | 17,452,210 |
ABOUT VITALHUB
Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.
VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps. The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 600+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.
CAUTIONARY STATEMENT
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$10.81 |
Daily Change: | -0.12 -1.10 |
Daily Volume: | 112,898 |
Market Cap: | C$549.690M |
November 13, 2024 October 30, 2024 August 08, 2024 July 30, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB